By Ilan Zipkin
Staff Writer

After seven years, six Phase III trials and one lost partner, Amylin Pharmaceuticals Inc. believes that it finally has the clinical data necessary to submit applications in mid-2000 for U.S. and European marketing approval of its Symlin pramlintide analog of the hormone amylin to treat Type I diabetes and insulin-dependent Type II diabetes.